---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010981"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T11:07:22.497493+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics reports FY2024 net loss $63.7M, cash $98.1M, pz-cel PDUFA April 29

## Summary
- Net loss of $63.7M ($1.55 per share) for FY2024 vs $54.2M ($2.53 per share) in FY2023.
- Cash and investments total $98.1M as of Dec 31, 2024, up from $52.6M; runway into 2026.
- FDA PDUFA target action date for pz-cel BLA is April 29, 2025; draft label received March 14.
- If approved, first patient treatment with pz-cel expected in Q3 2025; launch prep with five QTCs underway.
- Two additional patents for pz-cel extend protection to June 2037 and July 2040.

## SEC filing metadata
- accession: 0001493152-25-010981
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/0001493152-25-010981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010981
- JSON: https://secwatch.observer/filing/0001493152-25-010981.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.